X4 Pharmaceuticals (NASDAQ: XFOR) — Perfil da empresa, notícias e dados financeiros
X4 Pharmaceuticals develops therapies for rare diseases and immune disorders, focusing on WHIM syndrome.
X4 Pharmaceuticals
X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of rare diseases and immune system disorders. The company's lead product candidate, mavorixafor, is in late-stage clinical development aimed at treating WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and has potential applications in a broad range of cancer and autoimmune diseases. X4 Pharmaceuticals is dedicated to advancing its pipeline through scientific innovation and rigorous clinical studies, with the objective of improving the lives of patients battling serious diseases. Through its research and development efforts, the company aims to unlock the full potential of its therapies by addressing underserved medical needs.
Resumo
Operações
Produtos e/ou serviços de X4 Pharmaceuticals
- Mavorixafor, a CXCR4 antagonist aimed at treating WHIM syndrome and certain cancers.
- Clinical trials for the treatment of Severe Congenital Neutropenia with CXCR4 antagonist therapy.
- Development of next-generation CXCR4 antagonists for a range of cancers.
- Research on CXCR4 inhibitors for the potential treatment of Waldenstrom macroglobulinemia.
- Preclinical studies investigating the role of CXCR4 antagonism in multiple myeloma.
- Exploration of CXCR4-related therapies for improving hematopoietic stem cell transplantation.
equipe executiva do X4 Pharmaceuticals
- Adam R. CraigExecutive Chair
- John P. VolponePresident & COO
- David H. KirskeCFO, Treasurer & Corporate Secretary
- Richard PetersFounder
- Renato T. SkerljFounder
- Keith T. FlahertyFounder & Member of Corporate Advisory Board
Últimas notícias sobre a X4 Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela X4 Pharmaceuticals, em USD.
- Cap. de mercado
- 322,2 mi
- Receita (TTM)
- 15,8 mi
- P/L
- 162.5
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 35,1 mi | -86,9 mi | -79,2 mi | |
| 2,6 mi | -36,4 mi | -37,5 mi | |
| 0 | -107,5 mi | -101,2 mi | |
| 0 | -87,6 mi | -93,9 mi |